Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

A quarter of symptomatic kids hit by long COVID; mRNA shots provide best protection in breast milk

Mon, 14th Mar 2022 18:42

March 14 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.

One in four kids with COVID develop lingering problems

One in four children with COVID-19 symptoms develop "long COVID," according to data pooled from 21 earlier studies conducted in Europe, Asia, Australia and South America.

Among the 80,071 children with COVID-19 in the studies, 25% developed symptoms that lasted at least 4-to-12 weeks or new persistent symptoms that appeared within 12 weeks, researchers reported on Sunday on medRxiv https://www.medrxiv.org/content/10.1101/2022.03.10.22272237v1 ahead of peer review. The most frequent problems were neuropsychiatric (mood symptoms, fatigue, sleep disorders, headaches, cognitive alterations, dizziness, balance problems), cardiorespiratory (breathing difficulty, congestion, exercise intolerance, chest pain and tightness, cough, irregular heart rhythm), skin-related (excessive sweating, itchiness, hair loss) and gastrointestinal (abdominal pain, constipation, diarrhea, vomiting, and nausea). Analyses of data pooled from many different studies with different methodologies cannot yield firm conclusions, the researchers acknowledge. What is clear, however, is that "children and adolescents have also physical and mental health consequences derived from COVID-19," said study coauthor Sonia Villapol of Houston Methodist Research Institute in Texas.

"Identifying the main signs and symptoms of pediatric long COVID can help diagnose, develop better treatments, create multidisciplinary teams for optimal clinical management, and find risk factors for prevention."

Vaccine protection in mother's milk strongest after mRNA shots

Women who wish to pass protective antibodies induced by COVID-19 vaccines to their babies via breast milk should opt for the mRNA shots from Moderna or Pfizer/BioNTech , according to a study reported on Monday in JAMA Pediatrics https://jamanetwork.com/journals/jamapediatrics/fullarticle/2789947.

For the study, 124 lactating women each provided 17 milk samples over a period of 100 days. The women had received either an mRNA vaccine or a vector-based vaccine from Johnson & Johnson or AstraZeneca. Researchers measured two types of antibodies in the milk samples - IgA antibodies and IgG antibodies, both of which are thought to play important roles in protecting breastfed infants. Nearly all - 96% to 97% - of the women who received both doses of an mRNA vaccine had detectable IgA antibodies in their milk, while only 39% had antibodies in their milk after two doses of the AstraZeneca shot and 48% after the one-dose J&J vaccine. All the women who received both doses of the Pfizer/BioNTech, Moderna or AstraZeneca vaccines had IgG antibodies, compared to only 28% of women who received J&J's shot.

"An mRNA-based COVID-19 vaccine is the optimal choice for lactating women when they want to transfer breast milk antibodies to their infants," the researchers concluded.

Omicron is infectious on surfaces longer than original virus

Omicron particles remain infectious on surfaces for longer periods than particles of the original SARS-CoV-2, according to laboratory experiments.

Researchers put droplets of infectious virus from the original coronavirus version and the Omicron BA.1 variant on a variety of surfaces at room temperature. On smooth surfaces (glass, stainless steel and plastic sheet), Omicron was still infectious after seven days, whereas particles of the original SARS-CoV-2 were no longer infectious on stainless steel and plastic sheets by day 4 and on glass by day 7, the researchers reported on Thursday on bioRxiv https://www.biorxiv.org/content/10.1101/2022.03.09.483703v1 ahead of peer review. On tissue paper and printing paper, the original virus was no longer infectious at 30 minutes. Omicron was still infectious at 30 minutes, but no longer after an hour, the researchers said.

For the most part, SARS-CoV-2 is transmitted via respiratory droplets in the air. While infection via contact with contaminated surfaces is less common, the new study "highlights the importance of hand hygiene and cleaning on surfaces that are regularly touched by different persons," said study coauthor Leo Poon of the University of Hong Kong. "For surfaces and settings contaminated by a COVID-19 patient, proper cleaning should be done."

Click for a Reuters graphic https://tmsnrt.rs/3c7R3Bl on vaccines in development.

More News
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.